Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥2,848 JPY
Change Today +11.00 / 0.39%
Volume 84.6K
4569 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
As of 12:42 AM 04/22/15 All times are local (Market data is delayed by at least 15 minutes).

kyorin holdings inc (4569) Snapshot

Open
¥2,852
Previous Close
¥2,837
Day High
¥2,860
Day Low
¥2,824
52 Week High
03/12/15 - ¥3,040
52 Week Low
05/9/14 - ¥1,830
Market Cap
213.5B
Average Volume 10 Days
220.4K
EPS TTM
¥164.94
Shares Outstanding
74.9M
EX-Date
03/27/15
P/E TM
17.3x
Dividend
¥52.00
Dividend Yield
1.83%
Current Stock Chart for KYORIN HOLDINGS INC (4569)

Related News

No related news articles were found.

kyorin holdings inc (4569) Related Businessweek News

No Related Businessweek News Found

kyorin holdings inc (4569) Details

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical, generic, over-the-counter drugs, and others in Japan and internationally. The company operates in two segments, Pharmaceutical Business and Consumer Healthcare (Skincare) Business. Its products primarily include Flutiform, a drug for the treatment of asthma; Uritos, which is a therapeutic agent for overactive bladder; Kipres for the treatment of bronchial asthma and allergic rhinitis; Pentasa for the treatment of ulcerative colitis and Crohn’s disease; and Mucodyne, a mucoregulan drug. The company also offers Milton, a baby bottle disinfectant; Rubysta, a disinfectant cleaner; skincare and cosmetic products based on nanocapsule technology, a pharmaceutical formulation concept; and prescription medicines and quasi-drugs, diagnostics, and industrial chemicals. In addition, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies’ technologies and collection of information concerning clinical trials. Further, the company’s pipeline products include KRP-AB1102 and KRP-AB1102F for the treatment of chronic obstructive pulmonary disease that are under Phase III clinical development; KRP-AM1977X for the treatment of infectious diseases that is under Phase II clinical development; and KRP-114V and KRP-EPA605 for overactive bladder. Additionally, it pipeline products comprise KRP-209 for Tinnitus; KRP-203 for transplantation, autoimmune diseases, and IBD; KRP-AM1977X, an oral antibacterial agent; and KRP-AM1977Y, an injection. The company’s other pipeline products include Ad-SGE-REIC formulation, a gene-therapy product; and Dimethyl sulfoxide for the treatment of interstitial cystitis. KYORIN Holdings, Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

2,452 Employees
Last Reported Date: 06/25/14
Founded in 1923

kyorin holdings inc (4569) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyorin holdings inc (4569) Key Developments

Kyorin Holdings, Inc. Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2014; Provides Earnings Guidance for the Year Ending March 31, 2015; Provides Year End Dividend Guidance for the Year Ending March 31, 2015

KYORIN Holdings, Inc. reported consolidated earnings results for the nine months ended December 31, 2014. For the period, the company reported net sales of ¥83,602 million compared to ¥83,430 million a year ago. Operating income was ¥10,691 million compared to ¥13,503 million a year ago. Net income was ¥9,571 million or ¥128.10 per share compared to ¥9,272 million or ¥124.11 per share a year ago. For the full year ending March 31, 2015, the company expects ordinary income of ¥14,300 million, operating income of ¥13,800 million, and net income of ¥11,600 million or ¥155.26 per share on net sales of ¥111,700 million. The company expects to pay year end dividend of ¥32 per share for the year ending March 31, 2015 compared to ¥42 per share paid in the same period a year ago.

KYORIN Holdings, Inc. to Report Q3, 2015 Results on Feb 02, 2015

KYORIN Holdings, Inc. announced that they will report Q3, 2015 results on Feb 02, 2015

KYORIN Holdings, Inc. Presents at The 9th Annual Daiwa Investment Conference 2015, Mar-02-2015

KYORIN Holdings, Inc. Presents at The 9th Annual Daiwa Investment Conference 2015, Mar-02-2015 . Venue: The Prince Park Tower, 4-8-1, Shibakoen, Minato-ku, Tokyo, Japan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4569:JP ¥2,848.00 JPY +11.00

4569 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4569.
View Industry Companies
 

Industry Analysis

4569

Industry Average

Valuation 4569 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYORIN HOLDINGS INC, please visit www.kyorin-gr.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.